Cargando…

Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series

Brain metastases are common in patients with advanced breast cancer (BC), causing considerable morbidity and mortality. Eribulin is a microtubule dynamics inhibitor approved for treating certain patients with metastatic BC, previously treated with an anthracycline and a taxane. In the 301 phase 3 st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Alex Y, Ying, Xu Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444132/ https://www.ncbi.nlm.nih.gov/pubmed/26052228 http://dx.doi.org/10.4137/BCBCR.S21176

Ejemplares similares

Regression of brain metastases from breast cancer with eribulin: a case report
por: Matsuoka, Hiromichi, et al.
Publicado: (2013)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
por: Byun, Kyung-Do, et al.
Publicado: (2016)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study
por: Murakami, Manabu, et al.
Publicado: (2019)

Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report
por: Xie, Xiao-Feng, et al.
Publicado: (2022)

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
por: Zheng, Shengnan, et al.
Publicado: (2021)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

Development of interstitial pneumonia during treatment with eribulin: a case report
por: Nakamura, Kota, et al.
Publicado: (2017)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
por: Donovan, Diana, et al.
Publicado: (2014)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient
por: Tsunogae, Marie, et al.
Publicado: (2021)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers
por: Nakamura, Hajime, et al.
Publicado: (2022)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
por: Matsuura, Motoki, et al.
Publicado: (2023)

Eribulin-induced radiation recall dermatitis: a case report and brief review of the literature
por: Tran, William T, et al.
Publicado: (2020)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment
por: Takada, Kohichi, et al.
Publicado: (2019)

A Case Series of Breast Metastases from Different Extramammary Malignancies and Their Literature Review
por: Moreno-Astudillo, Liliana, et al.
Publicado: (2019)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
por: Tamiya, Hironari, et al.
Publicado: (2020)

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2020)

The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review
por: Zagami, Paola, et al.
Publicado: (2020)

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

CSF-ctDNA SMSEQ Analysis to Tailor the Treatment of a Patient with Brain Metastases: A Case Report
por: Huang, Wen-Tsung, et al.
Publicado: (2018)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2021)

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
por: Satomi-Tsushita, Natsuko, et al.
Publicado: (2019)

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells
por: Bellio, Chiara, et al.
Publicado: (2022)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mln40k9a92ibinps8800i3re9f